Form 8-K - Current report:
SEC Accession No. 0001193125-22-273339
Filing Date
2022-10-31
Accepted
2022-10-31 09:05:34
Documents
16
Period of Report
2022-10-31
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d363220d8k.htm   iXBRL 8-K 38858
2 EX-99.1 d363220dex991.htm EX-99.1 20838
3 EX-99.2 d363220dex992.htm EX-99.2 4272
7 GRAPHIC g363220snap0044.jpg GRAPHIC 11913
8 GRAPHIC g363220snap0045.jpg GRAPHIC 48035
  Complete submission text file 0001193125-22-273339.txt   283574

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA gmtx-20221031.xsd EX-101.SCH 2879
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE gmtx-20221031_lab.xml EX-101.LAB 17980
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gmtx-20221031_pre.xml EX-101.PRE 11274
10 EXTRACTED XBRL INSTANCE DOCUMENT d363220d8k_htm.xml XML 3405
Mailing Address 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE MA 02139
Business Address 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE MA 02139 (617) 401-4400
Gemini Therapeutics, Inc. /DE (Filer) CIK: 0001816736 (see all company filings)

EIN.: 851613057 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39438 | Film No.: 221343930
SIC: 2834 Pharmaceutical Preparations